Hepion Pharmaceuticals director Danina Fisher files initial beneficial ownership statement

Hepion Pharmaceuticals director Danina Fisher filed an initial Form 3 beneficial ownership statement with the SEC, covering her holdings as of July 1, 2026. The disclosure was published via EDGAR on July 8, 2026.

Hepion Pharmaceuticals director Danina Fisher filed an initial Form 3 disclosure covering her holdings as of July 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032515), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here